ACAD
34.33
+0.5
+1.48%
AEMD
2.23
-0.04
-1.76%
APRI
1.13
+0.02
+1.80%
ARNA
1.34
-0.04
-2.90%
ATEC
2.03
-0.1
-4.69%
CNAT
8.36
-0.41
-4.68%
CRXM
0.195
+0.012
+6.47541%
CYTX
1.03
-0.04
-3.74%
DXCM
77.96
+0.03
+0.04%
GNMK
12.82
-0.06
-0.47%
HALO
13.94
-0.05
-0.36%
ILMN
184.86
+1.12
+0.61%
INNV
0.09
0.00
-1.10%
INO
6.29
-0.14
-2.18%
ISCO
1.75
+0.08
+4.48%
ISIS
57.56
0.00
0.00%
LGND
111.17
-0.02
-0.02%
LPTN
2.93
-0.08
-2.66%
MBVX
2.27
+0.06
+2.71%
MEIP
1.59
0.00
0.00%
MNOV
5.75
-0.07
-1.20%
MRTX
4.55
-0.22
-4.71%
MSTX
0.131
-0.007
-5.278%
NBIX
53.4
-0.19
-0.35%
NUVA
72.51
-0.3
-0.41%
ONCS
1.15
+0.01
+0.88%
ONVO
2.9
+0.01
+0.35%
OREX
3.37
-0.24
-6.65%
OTIC
13.35
-0.3
-2.20%
QDEL
24.17
+0.02
+0.08%
RCPT
231.96
0.00
0.00%
RGLS
1.55
-0.05
-3.13%
RMD
67.99
-4.86
-6.67%
SPHS
2.578
+0.028
+1.0863%
SRNE
1.95
-0.15
-7.14%
TROV
0.93
+0.02
+2.46%
VICL
2.36
+0.05
+2.16%
VOLC
18
0.00
0.00%
ZGNX
11
0.00
0.00%
ACAD
34.33
+0.5
+1.48%
AEMD
2.23
-0.04
-1.76%
APRI
1.13
+0.02
+1.80%
ARNA
1.34
-0.04
-2.90%
ATEC
2.03
-0.1
-4.69%
CNAT
8.36
-0.41
-4.68%
CRXM
0.195
+0.012
+6.47541%
CYTX
1.03
-0.04
-3.74%
DXCM
77.96
+0.03
+0.04%
GNMK
12.82
-0.06
-0.47%
HALO
13.94
-0.05
-0.36%
ILMN
184.86
+1.12
+0.61%
INNV
0.09
0.00
-1.10%
INO
6.29
-0.14
-2.18%
ISCO
1.75
+0.08
+4.48%
ISIS
57.56
0.00
0.00%
LGND
111.17
-0.02
-0.02%
LPTN
2.93
-0.08
-2.66%
MBVX
2.27
+0.06
+2.71%
MEIP
1.59
0.00
0.00%
MNOV
5.75
-0.07
-1.20%
MRTX
4.55
-0.22
-4.71%
MSTX
0.131
-0.007
-5.278%
NBIX
53.4
-0.19
-0.35%
NUVA
72.51
-0.3
-0.41%
ONCS
1.15
+0.01
+0.88%
ONVO
2.9
+0.01
+0.35%
OREX
3.37
-0.24
-6.65%
OTIC
13.35
-0.3
-2.20%
QDEL
24.17
+0.02
+0.08%
RCPT
231.96
0.00
0.00%
RGLS
1.55
-0.05
-3.13%
RMD
67.99
-4.86
-6.67%
SPHS
2.578
+0.028
+1.0863%
SRNE
1.95
-0.15
-7.14%
TROV
0.93
+0.02
+2.46%
VICL
2.36
+0.05
+2.16%
VOLC
18
0.00
0.00%
ZGNX
11
0.00
0.00%
Home » Archive by Category

Xconomy

AnaptysBio Adds More Shares, Raises $75M in Stock Market Debut

January 26, 2017 – 9:59 am

AnaptysBio is the first U.S. biotech company to go public this year, raising $75 million in an IPO intended to finance development of antibody-based drugs for inflammatory disorders. The San…

[[Click headline to continue reading.]]

Just Four Months After Series A, Delinia Sells to Celgene For $300M

January 26, 2017 – 5:35 am

It didn’t take long for startup Delinia to entice a big drug developer: Just over four months after emerging from stealth and raising a Series A round, the company, developing drugs for a range of…

[[Click headline to continue reading.]]

Inspired by NFL Teammate, Aethlon Seeks Diagnostic for Brain Injuries

January 25, 2017 – 6:56 am

Just as the NFL marketing machine is stoking the build-up to Super Bowl LI, a San Diego diagnostic company headed by a former Denver Broncos player has unveiled plans for a new clinical study of…

[[Click headline to continue reading.]]

Anthem Caps Coverage Of Biogen Spine Drug Despite Wide FDA Approval

January 24, 2017 – 10:50 am

One of the nation’s major health insurers has placed limitations on access to the first-ever approved drug for the rare spinal muscular atrophy, validating patient fears that the high price tag of…

[[Click headline to continue reading.]]

Report: Biotech VCs Perpetuate Boardroom Gender Gap

January 24, 2017 – 6:39 am

If power in the business world is centered in the boardroom, women in biotech have a long way to go to get their fair share—and the venture community deserves much of the blame. That’s…

[[Click headline to continue reading.]]

Ex-FDA Commish Califf Gives Props to Patient Groups—With Caveats

January 23, 2017 – 11:40 am

The nation’s former Food and Drug Administration commissioner Robert Califf, appearing for the first time since he resigned last week, told a Silicon Valley crowd this morning that the FDA will…

[[Click headline to continue reading.]]

Bio Roundup: Tom Price, Patient Conflicts, Orphan Games & More

January 20, 2017 – 4:18 am

The new president of the United States, Donald Trump, is being sworn in today amid a storm of questions about the plans that he, and those who might work for him, have in store for American…

[[Click headline to continue reading.]]

Cytori Buys San Antonio-based Azaya’s Drug Delivery Tech for Stock

January 19, 2017 – 1:38 pm

San Antonio — Cytori Therapeutics, a San Diego, CA-based developer of drugs that use patients’ own fat tissues to make cellular therapies, is buying the assets of San Antonio-based Azaya…

[[Click headline to continue reading.]]

Dems Grill HHS Nominee Price About Trump Comments, Stock Holdings

January 18, 2017 – 2:03 pm

[Note: This report was co-authored by deputy biotech editor Ben Fidler.] Tom Price, the man who could oversee an overhaul of the U.S. healthcare system, answered often pointed questions this morning…

[[Click headline to continue reading.]]

Biotech Roundup: JPM Deals, Gender Diversity, PCSK9 Battle & More

January 13, 2017 – 6:07 am

[Corrected, 1/14/16, see below] This past week, the biopharma industry made its annual January pilgrimage to San Francisco for the J.P. Morgan Healthcare Conference. 2016 was a whirlwind year in…

[[Click headline to continue reading.]]